Please input keywords
RenMice™ HiTS Platform
Large-scale antibody drug development for 1000+ targets
Project Integrum is a unique and innovative large-scale drug development initiative initiated by Biocytogen, which is built upon the human antibody platform RenMice (RenMab, RenLite, and RenNano). It aims to target thousands of potential drug targets and establish six major technological platforms: fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (ADCs), nanobodies, TCR-mimic antibodies, and GPCR antibodies. These platforms are utilized for the development of antibody-based drugs in various forms such as monoclonal antibodies, bispecific antibodies, nanobodies, ADCs, TCR-mimic antibodies, and cell therapies, catering to the enormous global medical demand. With the formation of a rich diversity of high-quality antibody molecule library, the program is committed to achieving the goal of new drug development through innovation of technology and ideas with an open and cooperative attitude with global pharmaceutical companies.
Antibody Discovery
In Vivo Efficacy
Targetide ntification
Target KO RenMice
conserved region
Target gene
Protein expressed
Target gene knockout
Not expressed
non-homologous region
conserved region
Project Integrum

Open for partnership

As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMiceTM licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs).

We are actively seeking partnerships  Below are some of our disclosed partners.

Related news

Biocytogen Enters into Antibody Agreement with Merck

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

Biocytogen Enters Agreement with CtM Bio to Co-Develop TCR-Mimic Antibody based Multi-Specific T cell Engagers

Poster downloads

AACR 2022: Identifying New Therapeutic Antibodies Using Knockout Mice Expressing Human Immunoglobulin Variable Domain Genes

AACR 2023: The RenMice HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets